In Jan 2017, Regeneron received a major setback when the U.S District Court in Delaware granted Amgen's AMGN request for a permanent injunction prohibiting the sale of Praluent. The injunction relates to a patent infringement lawsuit that was filed by Amgen for the two patents (U.S. Patent Nos. 8,829,165, and 8,859,741) pertaining to Repatha. It follows a favorable jury verdict that was received by Amgen in Mar 2016.